Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion

Fig. 1

Hypoxia promotes resistance to temozolomide (TMZ) and affects its synergism with SKI-II. Dose–effect curves of (A) TMZ and (B) the sphingosine kinase inhibitor SKI-II on growth of NCH82 cells treated for 5 days. Data represent mean ± SD of n = 3. Combination index (CI) vs fraction affected (Fa) plots of 15 drug combinations of TMZ and SKI-II tested in NCH82 cells for 5 days at (C) 21% O2 and (D) 3% O2. CI = 1: additive effect. The sulforhodamine assay was used to determine the dose–effect curves and the CI. Data were obtained using the software CompuSyn from the mean of n = 3. Fa = 1 – (percentage of control cell growth/100)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us